Orexigen Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | |
|---|---|---|---|---|---|---|
| Revenue | $33.7M | $24.5M | $55.5M | $3.4M | $3.4M | $4.4M |
| Operating income | −$57.0M | −$60.1M | −$30.5M | −$77.2M | −$90.2M | −$27.9M |
| Net income | −$24.5M | −$68.7M | −$37.5M | −$77.7M | −$90.1M | −$28.1M |
| Total assets | $304.6M | $236.3M | $213.0M | $180.1M | $139.2M | $149.7M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $57.0M | $33.4M | $22.3M | $41.9M | $75.5M | $99.7M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 145.6M | 123.7M | 111.5M | 92.6M | 67.7M | 61.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- −169.0%
- Net margin
- −72.8%
- Return on equity
- −43.0%
- Return on assets
- −8.1%
- Return on capital (ROCE)
- −23.8%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $0.39
- Revenue growth (YoY)
- 37.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Accruals / assets
- 28.0%high accruals
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Baupost Group Llc/Ma10% owner | Oct 29, 2018 | Sell | 650,000 | $0.01 |
| Baupost Group Llc/Ma10% owner | Oct 24, 2018 | Sell | 28,000 | $0.01 |
| Moglia Stephen A.Officer — VP & Chief Accounting Officer | Mar 15, 2018 | Sell | 1,694 | $0.24 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivershipMay 23, 2019
- Regulation FD disclosureMay 3, 2019
- Regulation FD disclosureApr 2, 2019
- Regulation FD disclosureMar 4, 2019
- Regulation FD disclosureFeb 5, 2019
- Regulation FD disclosureDec 14, 2018
- Regulation FD disclosureDec 4, 2018
- Regulation FD disclosureOct 31, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4FORM 4Jun 4, 2019
- SC 13D/ANONEJun 4, 2019
- 15-12BMay 31, 2019
- 8-KMay 23, 2019
- 8-KMay 3, 2019
- CT ORDERApr 26, 2019
- 8-KApr 2, 2019
- 8-KFORM 8-KMar 4, 2019
- SC 13G/AAMENDMENT NO. 1 TO THE SCHEDULE 13GFeb 14, 2019
- SC 13G/AFeb 14, 2019
- SC 13G/AAMENDMENT NO. 1 TO SCHEDULE 13GFeb 12, 2019
- SC 13G/AAMENDMENT NO. 1 TO SCHEDULE 13GFeb 12, 2019
- SC 13G/AFeb 11, 2019
- 8-KFeb 5, 2019
- 8-KFORM 8-KDec 14, 2018
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.